Adial Pharmaceuticals, Inc vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| ADIL | LLY | |
|---|---|---|
| Market Cap | $8.71 million | $1.06 trillion |
| Revenue (TTM) | — | $79.67 billion |
| Net Income (TTM) | $-7,770,762 | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| ADIL | LLY | |
|---|---|---|
| P/E Ratio | — | 39.80 |
| Price / Book | 2.34 | 31.20 |
| Price / Sales | — | 13.27 |
ADIL leads on 1 of 1 valuation factors.
Profitability
| ADIL | LLY | |
|---|---|---|
| Net Margin | — | 33.53% |
| Return on Equity | -209.05% | 78.84% |
LLY leads on 1 of 1 profitability factors.
Dividend
| ADIL | LLY | |
|---|---|---|
| Dividend Yield | — | 0.58% |
| Payout Ratio | — | 23.23 |
ADIL and LLY split the dividend factors evenly.
Risk & Sentiment
| ADIL | LLY | |
|---|---|---|
| Short Interest | 0.00% | 1.29% |
ADIL leads on 1 of 1 risk & sentiment factors.
Dig deeper: ADIL overview, ADIL financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.